FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Lupin Pharmaceuticals Lisinopril and Hydrochlorothiazide Tablets Recall

Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12

Lupin Pharmaceuticals Inc. · Naples, FL

Risk level
Class II
Reported by FDA
Jul 23, 2025
Recall ID
D-0532-2025
Check your lot numberHow we source this data

Summary

Lupin Pharmaceuticals recalled Lisinopril and Hydrochlorothiazide Tablets starting Jun 20, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0532-2025 on Jul 23, 2025. Reason: Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg. Status: Ongoing.

Why it was recalled

Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.

Product description

Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, 100-count bottles, Rx only, Mfg for: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202, Manufactured by: Lupin Limited Nagpur-441 108, INDIA, NDC 68180-519-01

Lot numbers, UPCs & expiration codes

Lot #: QA01081, Exp. Date April 2027

Where it was sold

Product was distributed nationwide within the United States.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0532-2025
Classification
Class II
Status
Ongoing
Recall initiated
Jun 20, 2025
FDA report date
Jul 23, 2025
Quantity
58,968 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Lupin Pharmaceuticals Inc.

Original FDA data

Every field from FDA enforcement report D-0532-2025, exactly as published.

Show all FDA fields
City
Naples
State
FL
Status
Ongoing
Country
United States
Event ID
97118
Address
5801 Pelican Bay Blvd
Address (line 2)
Suite 500
Code information
Lot #: QA01081, Exp. Date April 2027
Postal code
34108-2755
Report date
Jul 23, 2025
Product type
Drugs
Recall number
D-0532-2025
Classification
Class II
Recalling firm
Lupin Pharmaceuticals Inc.
Product quantity
58,968 bottles
Reason for recall
Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, 100-count bottles, Rx only, Mfg for: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202, Manufactured by: Lupin Limited Nagpur-441 108, INDIA, NDC 68180-519-01
Distribution pattern
Product was distributed nationwide within the United States.
Recall initiation date
Jun 20, 2025
Center classification date
Jul 17, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0532-2025, published Jul 23, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls